Biomica

Biomica is an Israeli biotechnology company focused on developing microbiome-based therapeutics. It operates as a subsidiary of Evogene, a publicly traded life-sciences company, and is based in Rehovot, Israel. Biomica's work centers on discovering and developing live biotherapeutic products and microbiome-derived drug candidates intended to treat cancer and other diseases. The company's most prominent asset is BMC128, a microbiome-based therapeutic candidate that has completed a Phase 1 clinical trial. In a notable commercial development, Biomica entered into an exclusive worldwide licensing agreement with Lishan Biotech for BMC128, covering renal and lung cancer indications. This agreement marked a significant step in Biomica's strategy to advance its pipeline through partnerships. Following this transition, the Biomica website is no longer active, and the company directs inquiries to its parent, Evogene. Biomica therefore operates as an integrated part of the Evogene group, with its corporate communications and investor relations handled at the parent level. Its identity in the brand knowledge base is that of a specialized biotech sub-brand within the Evogene corporate house, rather than a standalone consumer-facing brand.

Biomica is an Israeli biotechnology company based in Rehovot and operating as a subsidiary of Evogene. It was established to develop microbiome-based therapeutics, an emerging field that seeks to harness the human microbiome for treating disease. As part of the Evogene group, Biomica benefits from the parent company's life-sciences infrastructure and corporate platform. The company's lead program, BMC128, is a microbiome-based therapeutic candidate for renal and lung cancer. BMC128 successfully completed a Phase 1 clinical trial, a key milestone for a clinical-stage microbiome company. Building on this result, Biomica entered into an exclusive worldwide licensing agreement with Lishan Biotech for BMC128, covering renal and lung cancer indications. This licensing deal represented a major commercial validation of Biomica's pipeline and shifted the asset into a partnership model. Following this transition, the Biomica website was deactivated, with the company directing stakeholders to Evogene for further information. This reflects Biomica's integration into the Evogene corporate structure, where it continues as a specialized biotech subsidiary rather than maintaining a separate public-facing web presence. The company's history is therefore closely tied to Evogene's broader strategy in life sciences and microbiome research.

• BMC128, a microbiome-based therapeutic for renal and lung cancer, successfully completed its Phase 1 clinical trial.

• Biomica entered into an exclusive worldwide licensing agreement with Lishan Biotech for BMC128.

• The Biomica website was deactivated as part of the transition, with information redirected to Evogene.

Clinical-stage microbiome therapeutics developer operating as a subsidiary of Evogene.

• BMC128

  A microbiome-based therapeutic for renal and lung cancer that has successfully completed its Phase 1 clinical trial.

• 2020.10.13

  Reported2020.10.13

  Biomica advances BMC128 to large-scale production[3]Biomica推进BMC128大规模生产prnewswire.com

  Biomica announced that its BMC128 live bacterial product candidate had advanced to large-scale production and the GMP production stage, in preparation for anticipated proof-of-concept clinical trials.

Read more

1. 1Biomicabiomicamed.com
2. 2Biomica (Israel) - Wikidatawikidata.org
3. 3Biomica推进BMC128大规模生产prnewswire.com